

PDN Referral Guide for Nevro HFX™ Spinal Cord Stimulation (SCS) Therapy



Diagnosed with Diabetes
Attempts to control patient's glucose have been made (medications, lifestyle, diet, etc)

HbA1c is less than or equal to 10%

Diagnosed with Diabetic Neuropathy
Other causes of neuropathy have been ruled out (e.g. alcohol, B12, chemoRx, thyroid, hepatitis, HIV) **Refer to neurologist if in doubt**
Pain is not related to peripheral vascular disease (i.e. pain of claudication)

Refractory to Conventional Medical Management (have tried and failed 2+ commonly prescribed PDN medications)

Lower limb pain intensity of 5 cm or more on a 10-cm visual analogue scale (VAS)

Deemed to be medically suitable for the procedure



REFER TO PAIN SPECIALIST FOR CONSIDERATION OF NEVRO HFX



Nevro HFX is the most effective treatment for painful diabetic neuropathy (PDN) patients that have tried and failed conventional medical management*



85% of patients get significant ($\geq 50\%$) relief¹



73% average pain relief at 18-months¹



63% of patients demonstrate neurologic improvements¹
(motor strength, reflexes, or sensory function)



92% of patients are satisfied with the treatment²



HFXforPDN.com/healthcare-providers

* Based on a review of published literature and reported outcomes studying SCS in PDN patients that are refractory to conventional treatment.

¹ Petersen E. et. al. Durability of 10 kHz spinal cord stimulation for painful diabetic neuropathy: 18-month results. NANS, Jan 2022.

² Petersen, E. et. al. Effect of High-frequency (10-kHz) Spinal Cord Stimulation in A Randomized Clinical Trial. JAMA Neurology, April 2021.

HFX is a comprehensive solution that includes a Senza™ Spinal Cord Stimulation system and support services for the treatment of chronic pain, including painful diabetic neuropathy programmed with a frequency of 10 kHz.

HFX and Senza are trademarks of Nevro Corp.

© 2022 Nevro Corp. All Rights Reserved. 20211012 Rev. C